H. White

发表

Door-to-needle times: Room for improvement and need for continuous audit

C. Edwards, H. White, 2000 .

New insights into the pathogenesis, prevention and management of acute coronary syndromes.

A. Tonkin, H. White, D. Amos, 1996, Australian and New Zealand journal of medicine.

THERAPEUTIC TRIALS IN CORONARY THROMBOSIS SHOULD MEASURE LEFT VENTRICULAR FUNCTION AS PRIMARY END-POINT OF TREATMENT

R. Norris, H. White, 1988, The Lancet.

Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy.

H. White, H. White, S. Cederholm-Williams, 1993, The American journal of cardiology.

Changes in serum lipid concentrations during first 24 hours after myocardial infarction.

R. Scragg, H. White, R. Marshall, 1987, British medical journal.

What contribution has cardiac surgery made to the decline in mortality from coronary heart disease?

J. Neutze, H. White, 1987, British medical journal.

Future of reperfusion therapy for acute myocardial infarction

H. White, 1999, The Lancet.

ACE inhibitors after myocardial infarction

H. White, 1990, The Lancet.

MECHANISM OF LATE BENEFIT IN ISIS-2

H. White, 1988, The Lancet.

Whatcontribution hascardiac surgerymadetothedecline in mortality fromcoronaryheart disease

J. Neutze, H. White, 1987 .

A heparin-controlled study of MK-383 in unstable angina

F. Werf, C. Nienaber, P. Théroux, 1994 .

The UK service level audit of insulin pump therapy in adults

H. White, N. Goenka, N. Furlong, 2014, Diabetic medicine : a journal of the British Diabetic Association.

See-sawing cardiovascular risk factors: a call for action in New Zealand.

H. White, 2006, The New Zealand medical journal.

Scandinavian simvastatin study (4S)

J. Slattery, J. McMurray, G. Thorgeirsson, 1994, The Lancet.

LEFT-VENTRICULAR FUNCTION AS AN END-POINT

R. Norris, H. White, 1989, The Lancet.

TRANSIENT SYMPTOMATIC HYPOTENSION IN PATIENTS ON SIMVASTATIN

H. White, JohnF. French, 1989, The Lancet.

GISSI-2 and the heparin controversy

H. White, 1990, The Lancet.

Guidelines for detection and management of dyslipidaemia. Scientific Committee of the National Heart Foundation of New Zealand.

R. Jackson, J. Neutze, J. Mann, 1993, The New Zealand medical journal.

Heart disease in Soweto: facing a triple threat

H. White, A. Dalby, 2008, The Lancet.

UK service level audit of insulin pump therapy in paediatrics

D. Hawcutt, H. White, P. Weston, 2015, Diabetic medicine : a journal of the British Diabetic Association.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

John Fuller, Luigi Tavazzi, John Wikstrand, 2019, The Lancet.

Society's expectation of the role of the doctor in New Zealand: results of a national survey.

H. White, A. Old, P. Foley, 2011, The New Zealand medical journal.

London Medical Schools

H. White, 1969 .

Angioplasty versus bypass surgery

J. Pepper, H. White, A. Marchbank, 1995, The Lancet.

Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary

H. White, H. D. White, 1994 .

LEVEEN SHUNTS

H. White, R. Arnot, 1978, The Lancet.

Thrombolytic therapy in the elderly

H. White, 2000, The Lancet.

Thrombolytic therapy for patients with myocardial infarction presenting after six hours

H. White, 1992, The Lancet.

Scandinavian simvastatin study (4S)

J. Slattery, J. McMurray, G. Thorgeirsson, 1994, The Lancet.

Thrombolytic therapy and mortality

H. White, 2001, The Lancet.

Coronary atheroma regression trials

B. Lewis, G. Watts, P. Seed, 1992, The Lancet.

Adherence and outcomes: it's more than taking the pills

H. White, 2005, The Lancet.

Liver disease induced by perhexiline maleate.

J. Horowitz, H. White, A. Goble, 1981, The Medical journal of Australia.

Management of unstable angina. Guidelines – 2000

A. Tonkin, J. Vinen, C. Aroney, 2001 .

Patients are patients.

H. White, J. Elliott, 1990, The New Zealand medical journal.

Thrombolysis for acute MI

H. White, JohnF. French, 1996, The Lancet.

Proposed new industry code on unhealthy food marketing to children and young people: will it make a difference?

S. Derrett, S. Hales, J. Potter, 2017, The New Zealand medical journal.

Scandinavian simvastatin study (4S)

H. White, 1994, Lancet.

Attitudes and practice of New Zealand doctors in the management of patients with dyslipidaemia.

H. White, J. Elliott, A. Bradley, 1993, The New Zealand medical journal.

Angioplasty versus bypass surgery

HarveyD White, H. White, 1995, The Lancet.

The 4S Study

J. Slattery, J. McMurray, G. Thorgeirsson, 1994 .

Aspirin or warfarin for non-rheumatic atrial fibrillation?

H. White, 1994, The Lancet.